undamentalytics Newsletter
Sign in

Vivosim Labs, Inc. cash flow statement

In fiscal 2026, Vivosim Labs, Inc.'s operations generated −$10.8m of cash; it spent $0 on capital projects, leaving free cash flow of −$10.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20102012Dec 20112013Dec 20122014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash from operations−1−2−10−16−20−29−29−29−20−15−13−8−12−15−9−11−10
Depreciation and amortisation00000111110000000
Stock-based pay00157977546222100
Capital spending00002210000000000
Free cash flow−1−2−10−16−21−31−31−29−20−15−14−9−13−15−9−11−10
Free cash flow after stock pay−1−2−11−20−28−40−38−36−26−19−19−11−15−16−10−11−10
Share buybacks—————————000—————
Shares issued———————913524001953

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IBIO vs VIVSLSTA vs VIVSAIM vs VIVS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vivosim Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivosim Labs, Inc.